<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCp q8y LQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+ 86293ac&amp;ff=20230823203531<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;ff=20230823203531" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 24 日星期四 00:35:33 +0000</lastbuilddate><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>钠基扑热息痛：对血压、心血管事件和全因死亡率的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37611115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>结论：这项研究并不支持之前关于在常规临床实践中短期使用对乙酰氨基酚碳酸氢钠会导致收缩压升高和心血管事件风险升高的建议。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 23 日：ehad535。doi：10.1093/eurheartj/ehad535。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：据报道，含有碳酸氢钠的扑热息痛泡腾制剂与血压升高、心血管疾病和全因死亡率较高的风险有关。考虑到这些发现的主要影响，对所报告的关联进行了重新审查。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用关联的电子健康记录数据，确定了 475 442 名至少服用过一种扑热息痛处方的英国人的队列，年龄在 60 至 90 岁之间。将服用钠基扑热息痛患者的结果与服用非钠扑热息痛患者的结果进行比较使用深度学习方法，研究了基线后 1 年内与收缩压 (SBP)、主要心血管事件（心肌梗死、心力衰竭和中风）以及全因死亡率的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 460 980 名和 14 462 名患者分别被确定为非钠基和钠基对乙酰氨基酚暴露组（平均年龄：74 岁；64% 为女性）。分析显示收缩压没有差异[平均差值] ]。-0.04 mmHg（95% 置信区间 -0.51, 0.43）]，与主要心血管事件无关[相对风险 (RR) 1.03 (0.91, 1.16)]。钠基扑热息痛与全因死亡率呈正相关[RR 1.46 (1.40, 1.52)].然而，在进一步考虑残留混杂的其他来源后，观察到的关联性向零衰减[RR 1.08 (1.01, 1.16)]。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究并不支持之前关于在常规临床实践中短期使用对乙酰氨基酚碳酸氢钠会导致收缩压升高和心血管事件风险升高的建议。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37611115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37611115</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad535>10.1093/eurheartj/ehad535</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37611115</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>希希尔·拉奥</dc:creator><dc:creator>米拉德·纳扎尔扎德</dc:creator><dc:creator>德克斯特·卡诺伊</dc:creator><dc:creator>李义宽</dc:creator><dc:creator>黄晶</dc:creator><dc:creator>穆罕默德·马穆埃</dc:creator><dc:creator>古拉姆雷扎·萨利米-霍尔希迪</dc:creator><dc:creator>阿莱塔·E·舒特</dc:creator><dc:creator>布鲁斯·尼尔</dc:creator><dc:creator>乔治·戴维·史密斯</dc:creator><dc:creator>卡齐姆·拉希米</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>钠基扑热息痛：对血压、心血管事件和全因死亡率的影响</dc:title><dc:identifier>下午：37611115</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad535</dc:identifier></item><item><title>女性、血脂和动脉粥样硬化性心血管疾病：欧洲动脉粥样硬化协会的行动呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/37611089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>心血管疾病是全球女性和男性死亡的主要原因，其中大多数归因于动脉粥样硬化性心血管疾病 (ASCVD)。尽管在过去 30 年中取得了进展，但 ASCVD 死亡率目前仍在增加，其中中年女性的相对增幅最快。漏诊或延迟诊断以及治疗不足并不能完全解释这种疾病负担。性别特异性因素，例如妊娠期高血压疾病、过早绝经（尤其是原发性卵巢... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 23 日：ehad472。doi：10.1093/eurheartj/ehad472。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心血管疾病是全球女性和男性死亡的主要原因，其中大多数归因于动脉粥样硬化性心血管疾病 (ASCVD)。尽管在过去 30 年中取得了进展，但 ASCVD 死亡率目前仍在增加，其中中年女性的相对增幅最快。漏诊或延迟诊断以及治疗不足并不能完全解释这种疾病负担。性别特异性因素，例如妊娠期高血压疾病、过早绝经（尤其是原发性卵巢功能不全）和多囊卵巢综合征也与此相关，有充分的证据表明这些因素与与更大的心血管风险相关。欧洲动脉粥样硬化协会的这一立场声明重点关注这些因素，以及女性一生中对脂质（包括脂蛋白（a））的性别特异性影响，这些影响会影响 ASCVD 风险。糖尿病、慢性肾病和自身免疫性炎症性疾病。所有这些影响都因与性别相关的社会文化因素而加剧。本小组强调需要尽早识别和治疗女性可改变的心血管危险因素，特别是对于那些处于危险中的女性由于特定性别的条件，以减少女性 ASCVD 难以接受的高负担。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37611089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37611089</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad472>10.1093/eurheartj/ehad472</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37611089</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>珍妮·E·罗特斯·范·伦内普</dc:creator><dc:creator>拉莱·托克佐格鲁</dc:creator><dc:creator>莉娜·巴迪蒙</dc:creator><dc:creator>——桑德拉·M·杜曼斯基</dc:creator><dc:creator>玛莎·古拉蒂</dc:creator><dc:creator>康妮·N·赫斯</dc:creator><dc:creator>克尔斯滕·霍尔文</dc:creator><dc:creator>玛丽亚姆·卡沃西</dc:creator><dc:creator>梅拉尔·凯克奇奥鲁</dc:creator><dc:creator>埃丝特·鲁特根斯</dc:creator><dc:creator>艾琳·D·米科斯</dc:creator><dc:creator>伊娃·普雷斯科特</dc:creator><dc:creator>简·K·斯托克</dc:creator><dc:creator>安妮·蒂贾格-汉森</dc:creator><dc:creator>玛丽克·JH·韦尔默</dc:creator><dc:creator>玛丽安·本</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>女性、血脂和动脉粥样硬化性心血管疾病：欧洲动脉粥样硬化协会的行动呼吁</dc:title><dc:identifier>下午：37611089</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad472</dc:identifier></item><item><title>二叶式主动脉瓣：长期发病率和死亡率</title><link/>https://pubmed.ncbi.nlm.nih.gov/37611071/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>结论：BAV 疾病表现出较高的终生发病率，到 90 岁时，主动脉瓣膜病几乎不可避免。感染性心内膜炎的终生发病率高于主动脉夹层。最常见的 BAV 临床表现是典型的主动脉瓣膜病，伴有保留了预期的长期生存，而复杂的瓣膜主动脉病表现会导致更高的死亡率。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 23 日：ehad477。doi：10.1093/eurheartj/ehad477。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：二叶式主动脉瓣 (BAV) 是最常见的先天性心脏畸形。社区 BAV 患者的终生发病率和长期生存率是否因 BAV 患者亚组而异尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：作者回顾性地确定了 1980 年 1 月 1 日至 2009 年 12 月 31 日期间所有奥姆斯特德县（明尼苏达州）超声心动图诊断为 BAV 的居民，包括典型瓣膜主动脉病患者（不伴有加速性瓣膜主动脉病或相关疾病的 BAV 患者）和患有 BAV 的患者。复杂性主动脉瓣病（BAV 伴有加速性主动脉瓣病或相关疾病）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：652 名连续诊断的 BAV 患者[中位 (IQR) 年龄为 37 (22-53) 岁；525 名 (81%) 成人和 127 名 (19%) 儿童] 接受随访，中位 (IQR) 为 19.1 (12.9-25.8)终生累积发病率（从出生到90岁）为86%（95% CI 82.5-89.7）；累积终生进展至≥中度主动脉瓣狭窄或反流、主动脉瓣手术、主动脉瘤≥45 mm或z评分≥ 3、主动脉手术、感染性心内膜炎和主动脉夹层分别为80.3%、68.5%、75.4%、27%、6%和1.6%。典型瓣膜-主动脉病患者的生存率[562（86%），年龄40]（ 28-55) 岁，86% 成人] 与年龄-性别匹配的明尼苏达州人口相似 (P = .12)。相反，复杂瓣膜主动脉病患者的生存率 [90 (14%)，14 岁 (3- 26) ）年，57% 儿科]低于预期，相对超额死亡风险为 2.25 (95% CI 1.21-4.19) (P = .01)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：BAV 疾病表现出较高的终生发病率，到 90 岁时，主动脉瓣膜病几乎不可避免。感染性心内膜炎的终生发病率高于主动脉夹层。最常见的 BAV 临床表现是典型的主动脉瓣膜病，伴有保留了预期的长期生存，而复杂的瓣膜主动脉病表现会导致更高的死亡率。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37611071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37611071</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad477>10.1093/eurheartj/ehad477</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37611071</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>杨立潭</dc:creator><dc:creator>子夜</dc:creator><dc:creator>穆罕默德·瓦吉·乌拉更多</dc:creator><dc:creator>约瑟夫·J·马莱泽夫斯基</dc:creator><dc:creator>克里斯托弗·斯科特</dc:creator><dc:creator>拉纳萨里巴东</dc:creator><dc:creator>索林·V·皮斯拉鲁</dc:creator><dc:creator>乌伊西勒·T·恩科莫</dc:creator><dc:creator>苏尼尔·V·曼卡德</dc:creator><dc:creator>帕特里夏·佩利卡</dc:creator><dc:creator>吴宰康</dc:creator><dc:creator>维罗尼克·L·罗杰</dc:creator><dc:creator>莫里斯·恩里克斯·萨拉诺</dc:creator><dc:creator>赫克托一世·米凯莱娜</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>二叶式主动脉瓣：长期发病率和死亡率</dc:title><dc:identifier>下午：37611071</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad477</dc:identifier></item><item><title>糖尿病心脏病学：一个新的亚专业？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37611068/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 23 日：ehad541。doi：10.1093/eurheartj/ehad541。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37611068/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37611068</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad541>10.1093/eurheartj/ehad541</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37611068</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>尤金·布劳瓦尔德</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>糖尿病心脏病学：一个新的亚专业？</dc:title><dc:identifier>下午：37611068</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad541</dc:identifier></item><item><title>钠-葡萄糖协同转运蛋白 2 抑制剂和盐皮质激素受体拮抗剂在心力衰竭中的协同作用：需要两个人才能探戈</title><link/>https://pubmed.ncbi.nlm.nih.gov/37611060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 23 日：ehad540。doi：10.1093/eurheartj/ehad540。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37611060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37611060</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad540>10.1093/eurheartj/ehad540</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37611060</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>约翰·鲍尔萨克斯</dc:creator><dc:creator>萨米拉·索尔塔尼</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>钠-葡萄糖协同转运蛋白 2 抑制剂和盐皮质激素受体拮抗剂在心力衰竭中的协同作用：需要两个人才能探戈</dc:title><dc:identifier>下午：37611060</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad540</dc:identifier></item><item><title>超声心动图深度学习检测重度主动脉瓣狭窄</title><link/>https://pubmed.ncbi.nlm.nih.gov/37611002/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>结论：本研究开发并外部验证了一种使用单视图 2D 超声心动图检测严重 AS 的自动化方法，具有用于床旁筛查的潜在实用性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 23 日：ehad456。doi：10.1093/eurheartj/ehad456。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：主动脉瓣狭窄 (AS) 的早期诊断对于预防发病率和死亡率至关重要，但需要使用多普勒成像进行熟练的检查。本研究报告了一种依赖于二维 (2D) 胸骨旁的新型深度学习模型的开发和验证来自经胸超声心动图的长轴视频，无需多普勒成像，可识别严重的 AS，适合床旁超声检查。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法和结果：在 2016 年至 2020 年 [康涅狄格州耶鲁纽黑文医院 (YNHH)] 的 5257 项研究（17570 个视频）训练集中，开发了一个三维卷积神经网络集成来检测严重的 AS，利用用于标签高效模型开发的自监督对比预训练。这种深度学习模型在 YNHH 的一组时间上不同的 2040 项连续研究（从 2021 年开始）以及两个地理上不同的队列（来自加利福尼亚州和其他医院的 4226 项和 3072 项研究）中得到了验证。深度学习模型在时间上不同的测试集中检测严重 AS 的受试者工作特征曲线 (AUROC) 下面积 (AUROC) 达到 0.978 (95% CI: 0.966, 0.988)，并在地理上不同的测试集中保持其诊断性能队列[加利福尼亚州为 0.952 AUROC (95% CI: 0.941, 0.963)，新英格兰为 0.942 AUROC (95% CI: 0.909, 0.966)]。该模型可通过识别主动脉瓣、二尖瓣环和左心房的显着图进行解释在非严重 AS 病例中，预测概率与较差的 AS 定量指标相关，表明与 AS 严重程度的各个阶段相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：本研究开发并外部验证了一种使用单视图 2D 超声心动图检测严重 AS 的自动化方法，具有用于床旁筛查的潜在实用性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37611002/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37611002</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad456>10.1093/eurheartj/ehad456</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37611002</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>格雷戈里·霍尔斯特</dc:creator><dc:creator>埃万杰洛斯·K·奥伊科诺莫</dc:creator><dc:creator>博巴克·J·莫尔塔扎维</dc:creator><dc:creator>安德烈亚斯·科皮更多</dc:creator><dc:creator>卡米尔·F·法里迪</dc:creator><dc:creator>——爱德华·J·米勒</dc:creator><dc:creator>约翰·K·福雷斯特</dc:creator><dc:creator>——罗伯特·L·麦克纳马拉</dc:creator><dc:creator>露西拉·奥诺-马查多</dc:creator><dc:creator>尼尔·袁</dc:creator><dc:creator>Aakriti Gupta更多</dc:creator><dc:creator>欧阳大卫</dc:creator><dc:creator>哈伦·M·克鲁霍尔兹</dc:creator><dc:creator>王张扬</dc:creator><dc:creator>罗汉凯拉</dc:creator><dc:date>2023-08-23</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>超声心动图深度学习检测重度主动脉瓣狭窄</dc:title><dc:identifier>下午：37611002</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad456</dc:identifier></item><item><title>对疑似冠状动脉疾病的稳定门诊患者进行延迟检测：精确随机临床试验的预先指定二次分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610768/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在患有疑似 CAD 的有症状参与者中，通过 PMRS 确定的最小风险指导了最初推迟测试的策略。该策略是安全的，没有观察到不良结果事件，无阻塞性 CAD 的插管次数较少，与平常相比，症状缓解类似测试。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2614。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：指南建议推迟对疑似冠状动脉疾病 (CAD) 且预检概率较低的有症状人群进行检测。据我们所知，尚无随机试验对这一策略进行前瞻性评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估推迟检测时被确定为 CAD 风险最低的人群的护理过程和健康结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这项随机、务实的有效性试验包括在 65 个北美和欧洲地点进行的 PRECISE 试验的预先指定的亚组分析。通过经过验证的 PROMISE 最低风险评分 (PMRS) 确定为最低风险的参与者也包括在内。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：使用 PMRS 进行精确策略的随机化，将那些风险最小的人分配到延迟测试，将其他人分配到冠状动脉计算机断层扫描血管造影，并使用选择性计算机断层扫描衍生的血流储备分数，或进行常规测试（压力测试或屏蔽 PMRS 的导管插入术）。按 PMRS 风险进行随机分层。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果：全因死亡、非致命性心肌梗塞 (MI) 或 12 个月内无阻塞性 CAD 插管的综合结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 2103 名参与者中，422 名被确定为最低风险 (20%)，并随机接受延迟测试 (n = 214) 或常规测试 (n = 208)。平均年龄 (SD) 为 46 (8.6) 岁；304 名女性(72%)。在随访期间，随机分配到延迟测试的人中有 138 人从未进行过测试 (64%)，而 76 人进行了下游测试 (36%)（中位 [IQR] 48 [15-78] 天）恶化 (30%)、不受控制 (10%) 或新症状 (6%)，或改变临床医生偏好 (19%) 或参与者偏好 (10%)。这些测试中 96% 的结果正常。发生在 2 次推迟测试参与者 (0.9%) 和 13 名常规测试参与者 (6.3%)（风险比，0.15；95% CI，0.03-0.66；P = .01）。延迟测试参与者中没有观察到死亡或心肌梗死，而 1 名非心血管死亡1 例 MI 发生在常规测试组。延迟测试组有 2 名参与者 (0.9%) 进行了无阻塞性 CAD 的导管插入术，12 名参与者 (5.8%) 进行了常规测试 (P = .02)。在基线时，70% 的参与者有12 个月时，两组的频繁心绞痛减少率均低于 20%。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在患有疑似 CAD 的有症状参与者中，通过 PMRS 确定的最小风险指导了最初推迟测试的策略。该策略是安全的，没有观察到不良结果事件，无阻塞性 CAD 的插管次数较少，与平常相比，症状缓解类似测试。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT03702244。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610768/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610768</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2614>10.1001/jamacardio.2023.2614</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610768</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——詹姆斯·E·乌德尔森</dc:creator><dc:creator>米歇尔·D·凯尔西</dc:creator><dc:creator>迈克尔·G·南纳</dc:creator><dc:creator>——克里斯托弗·B·福代斯</dc:creator><dc:creator>尤里克</dc:creator><dc:creator>——罗伯特·M·克莱尔</dc:creator><dc:creator>丹尼尔·B·马克</dc:creator><dc:creator>马内什·R·帕特尔</dc:creator><dc:creator>坎贝尔·罗杰斯</dc:creator><dc:creator>尼克·科森</dc:creator><dc:creator>詹卢卡·庞托内</dc:creator><dc:creator>帕尔·毛罗维奇-霍瓦特</dc:creator><dc:creator>伯纳德·德布劳内</dc:creator><dc:creator>——约翰·P·格林伍德</dc:creator><dc:creator>维克托·马里内斯库</dc:creator><dc:creator>乔纳森·莱普西克</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:creator>奥里·本-耶胡达</dc:creator><dc:creator>科林·贝瑞</dc:creator><dc:creator>谢伊·霍根</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>齐亚德·阿​​里</dc:creator><dc:creator>——罗伯特·A·伯恩</dc:creator><dc:creator>——克里斯托弗·M·克莱默</dc:creator><dc:creator>——罗伯特·W·叶</dc:creator><dc:creator>贝丝·马丁内斯更多</dc:creator><dc:creator>莎拉·马伦</dc:creator><dc:creator>惠特尼·休伊</dc:creator><dc:creator>——凯文·J·安斯特罗姆</dc:creator><dc:creator>侯赛因·卡里迪</dc:creator><dc:creator>凯伦·奇斯韦尔</dc:creator><dc:creator>斯里坎特·韦穆拉帕利</dc:creator><dc:creator>帕梅拉·道格拉斯</dc:creator><dc:creator>精确调查员</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>对疑似冠状动脉疾病的稳定门诊患者进行延迟检测：精确随机临床试验的预先指定二次分析</dc:title><dc:identifier>下午：37610768</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2614</dc:identifier></item><item><title>微血管心绞痛患者的冠状静脉压和微血管血流动力学：一项随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610757/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>结论和相关性：冠状静脉压升高导致微血管心绞痛患者微血管阻力降低，这种机制对这种复杂疾病的治疗具有潜在影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2566。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：冠状静脉循环在调节心肌灌注中的作用及其治疗微血管心绞痛的潜力尚未被探索。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估冠状静脉压的增加是否会改变微血管心绞痛患者的微血管阻力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这是一项盲法、假对照、交叉随机临床试验，在 2021 年 11 月至 2023 年 1 月期间招募了参与者。这项生理学终点研究的参与者是从德国美因茨。因微血管功能障碍（根据基于热稀释的微血管阻力指数 >;25 mm Hg × s 定义）而患有中度/重度心绞痛（加拿大心血管学会 2-4 级）的患者。排除标准为心外膜冠状动脉疾病.、二度和三度房室传导阻滞、严重瓣膜性心脏病、心肌病、肺病或肾病。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：将放置在心脏冠状窦（CS）中的尺寸较小的气球（以下简称气球）充气，将放气的气球放置在右心房中，称为假手术。在休息时和最大冠状动脉充血期间进行测量。最后评估者对随机序列不知情。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和测量：血流动力学参数，包括主动脉 (Pa) 和远端 (Pd) 冠状动脉压力、冠状窦压力 (Pcs)、右心房压力 (Pra) 和平均通过时间（血流倒数 [Tmn]），被测量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：本研究共纳入 20 名患者（中位 [IQR] 年龄，69 [64-75] 岁；11 名女性 [55.0%]）。其中 2 名患者 (10%) 患有糖尿病，6 名患者 (30%) 患有糖尿病。高胆固醇血症，15 名（75%）患有高血压，3 名（15%）是经常吸烟者。CS 球囊的充气导致静息时和充血期间的 CS 压力显着增加（与对照组相比，分别增加了 300% 和 317%）假手术，均 P &lt; .001），充血远端冠状动脉压力降低（中位 [IQR]，假手术：98 [88-110] mm Hg；球囊：89 [84-102] mm Hg；P = .01）和中位 (IQR) 通过时间（假手术：0.39 [0.23-0.62] s；球囊：0.26 [0.17-0.46] s；P &lt; .001）。因此，CS 闭塞导致静息冠状动脉阻力（中位）下降[IQR]，假手术：59 [37-87] mm Hg × s；球囊：42 [31-67] mm Hg × s；P = .005）和主要终点充血性冠状动脉阻力（平均 [IQR]，假手术）球囊：14 [8-26] mm Hg × s；P &lt; .001)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：冠状静脉压升高导致微血管心绞痛患者微血管阻力降低，这种机制对这种复杂疾病的治疗具有潜在影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT05034224。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610757/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610757</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2566>10.1001/jamacardio.2023.2566</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610757</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>海伦·乌尔里希</dc:creator><dc:creator>菲利普·哈默</dc:creator><dc:creator>马克西米利安·奥尔舍夫斯基</dc:creator><dc:creator>托马斯·明泽尔</dc:creator><dc:creator>哈维尔扫描</dc:creator><dc:creator>托马索·戈里</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>微血管心绞痛患者的冠状静脉压和微血管血流动力学：一项随机临床试验</dc:title><dc:identifier>下午：37610757</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2566</dc:identifier></item><item><title>低风险胸痛延迟检测的建议——已有数十年历史，但现在终于得到了检测</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610740/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2715。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610740/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610740</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2715>10.1001/jamacardio.2023.2715</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610740</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>雷蒙德·J·吉本斯</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>低风险胸痛延迟检测的建议——已有数十年历史，但现在终于得到了检测</dc:title><dc:identifier>下午：37610740</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2715</dc:identifier></item><item><title>美国鱼油补充剂的健康声明和剂量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>结论：这项横断面研究的结果表明，大多数鱼油补充剂标签都做出了健康声明，通常以结构/功能声明的形式，暗示对各种器官系统的健康益处，尽管缺乏试验数据表明功效。现有补充剂中 EPA+DHA 的每日剂量存在显着的异质性，导致补充剂之间的安全性和功效存在潜在差异。对膳食补充剂的监管加强…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2424。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：尽管多项随机临床试验显示，没有关于补充剂范围剂量对心血管有益的数据，但在 60 岁以上的美国成年人中，有五分之一经常服用鱼油补充剂来维持心脏健康。补充剂标签上的声明可能会影响消费者对健康益处的看法。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估美国鱼油补充剂标签上的健康声明，并检查常用配方中二十碳五烯酸 (EPA) 和二十二碳六烯酸 (DHA) 的剂量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这项横断面研究使用了来自美国国立卫生研究院膳食补充剂标签数据库的市售鱼油（和非鱼 ω-3 脂肪酸）补充剂标签数据。分析时间为 2022 年 2 月至 6 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：对鱼油标签上健康声明的频率和类型（美国食品和药物管理局 [FDA] 审查的合格健康声明与结构/功能声明）以及所引用的器官系统进行了评估。对来自 16 家领先制造商和零售商的 DHA (EPA+DHA) 补充剂进行了评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 2819 种独特的鱼油补充剂中，2082 种 (73.9%) 至少提出了 1 项健康声明。其中，只有 399 种 (19.2%) 使用了 FDA 批准的合格健康声明；其余的 (1683 种 [80.8%]) 仅做出了结构/功能声明（例如，“促进心脏健康”）。心血管健康声明是最常见的（1747 [62.0%]）。在 16 个领先品牌/制造商中，确定了 255 种鱼油补充剂。每日 EPA 剂量（中位数 [IQR]，340 [135-647] mg/d)、DHA（中位数 [IQR]，270 [140-500] mg/d）和总 EPA+DHA（中位数 [IQR]，600 [300-1100] ] mg/d)。在评估的 255 种补充剂中，只有 24 种 (9.4%) 含有每日剂量 2 克或更多的 EPA+DHA。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项横断面研究的结果表明，大多数鱼油补充剂标签都做出了健康声明，通常以结构/功能声明的形式，暗示对各种器官系统的健康益处，尽管缺乏试验数据表明功效。现有补充剂中 EPA+DHA 的每日剂量存在显着的异质性，导致补充剂之间的安全性和功效存在潜在差异。可能需要加强膳食补充剂标签的监管，以防止消费者错误信息。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610733</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2424>10.1001/jamacardio.2023.2424</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610733</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乔安娜·N·阿萨杜里安</dc:creator><dc:creator>——埃里克·D·彼得森</dc:creator><dc:creator>塞缪尔·麦克唐纳</dc:creator><dc:creator>阿南德·古普塔更多</dc:creator><dc:creator>——安-玛丽·纳瓦尔</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>美国鱼油补充剂的健康声明和剂量</dc:title><dc:identifier>下午：37610733</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2424</dc:identifier></item><item><title>为疑似冠状动脉疾病制定精确诊断策略——从 PRECISE 试验中汲取的经验教训</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610732/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2696。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610732/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610732</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2696>10.1001/jamacardio.2023.2696</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610732</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>克里希纳·K·帕特尔</dc:creator><dc:creator>莱斯利·J·肖</dc:creator><dc:date>2023-08-23</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>为疑似冠状动脉疾病制定精确诊断策略——从 PRECISE 试验中汲取的经验教训</dc:title><dc:identifier>下午：37610732</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2696</dc:identifier></item><item><title>对疑似冠状动脉疾病的症状稳定的患者进行基于风险的初始检测策略与常规检测的比较：精确随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37610731/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230823203531&amp;v=2.17.9.post6+86293ac<description>结论和相关性：稳定胸痛的初步诊断方法从定量风险分层开始，对最低风险患者进行延迟测试，并在所有其他患者中进行选择性 FFR-CT 的 cCTA 相对于 UT 提高 1 年的临床效率。需要验证这些发现，包括安全。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 8 月 23 日。doi：10.1001/jamacardio.2023.2595。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：对稳定胸痛患者进行的初步评估显示，与压力测试相比，使用冠状动脉计算机断层扫描血管造影 (cCTA) 进行的初步评估具有相同或更好的结果，这些试验为指南提供了参考，但提出了关于过度测试和过度插管的问题。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：测试修改后的初始 cCTA 策略，该策略旨在与常规测试 (UT) 相比提高临床效率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：这是一项务实的随机临床试验，招募了2018年12月3日至2021年5月18日的参与者，中位随访时间为11.8个月。来自北美和欧洲65个地点且症状稳定的患者疑似冠状动脉疾病 (CAD) 且既往未进行过检测的患者以 1:1 的比例随机分配至精准策略 (PS) 或 UT。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预措施：PS 纳入了评估胸痛的前瞻性多中心影像研究 (PROMISE) 最低风险评分，以定量选择最低风险参与者进行延期测试，将所有其他参与者分配给具有选择性 CT 衍生血流储备分数 (FFR-CT) 的 cCTA UT 包括选定地点的压力测试或导管插入术。现场临床医生决定后续护理。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结局和指标：结局是将临床效率（无阻塞性 CAD 的侵入性导管插入术）和安全性（死亡或非致命性心肌梗塞 [MI]）合并为复合主要终点。次要终点包括主要结局的安全性组成部分和药物使用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有 2103 名参与者（平均 [SD] 年龄，58.4 [11.5] 岁；1056 名男性 [50.2%]）被纳入研究，1057 名参与者中有 44 名参与者中有 422 名 [20.1%] 被归类为最低风险。 PS 组中有 118 名参与者 (4.2%)，UT 组有 1046 名参与者中的 118 名参与者 (11.3%)（风险比 [HR]，0.35；95% CI，0.25-0.50）。PS，无阻塞性疾病的导管插入率较低(27 [2.6%]) 与 UT 参与者 (107 [10.2%]；HR，0.24；95% CI，0.16-0.36)。HR，1.52；95% CI，0.73-3.15)。5 人死亡 (0.5 PS 组有 7 例 (0.7%) 发生，而 UT 组有 7 例 (0.7%) (HR, 0.71; 95% CI, 0.23-2.23)，PS 组有 13 例 (1.2%) 发生非致命性心梗，而 UT 组有 5 例 (0.5%) ）在 UT 组（HR，2.65；95% CI，0.96–7.36）。%] 对比 873 例中的 365 例 [41.8%]）和抗血小板药物（900 例中的​​ 321 例 [35.7%] 对比 873 例中的 237 例 [27.1%]） 1 年时，PS 组的死亡率高于 UT 组（均 P &lt; . 001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：稳定胸痛的初步诊断方法从定量风险分层开始，对最低风险患者进行延迟测试，并在所有其他患者中进行选择性 FFR-CT 的 cCTA 相对于 UT 提高 1 年的临床效率。需要验证这些发现，包括安全。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov 标识符：NCT03702244。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37610731/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610731</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.2595>10.1001/jamacardio.2023.2595</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37610731</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator>帕梅拉·道格拉斯</dc:creator><dc:creator>迈克尔·G·南纳</dc:creator><dc:creator>米歇尔·D·凯尔西</dc:creator><dc:creator>尤里克</dc:creator><dc:creator>丹尼尔·B·马克</dc:creator><dc:creator>马内什·R·帕特尔</dc:creator><dc:creator>坎贝尔·罗杰斯</dc:creator><dc:creator>——詹姆斯·E·乌德尔森</dc:creator><dc:creator>——克里斯托弗·B·福代斯</dc:creator><dc:creator>尼克·科森</dc:creator><dc:creator>詹卢卡·庞托内</dc:creator><dc:creator>帕尔·毛罗维奇-霍瓦特</dc:creator><dc:creator>伯纳德·德布劳内</dc:creator><dc:creator>——约翰·P·格林伍德</dc:creator><dc:creator>维克托·马里内斯库</dc:creator><dc:creator>乔纳森·莱普西克</dc:creator><dc:creator>Gregg W Stone</dc:creator><dc:creator> Ori Ben-Yehuda</dc:creator><dc:creator> Colin Berry</dc:creator><dc:creator> Shea E Hogan</dc:creator><dc:creator> Bjorn Redfors</dc:creator><dc:creator> Ziad A Ali</dc:creator><dc:creator> Robert A Byrne</dc:creator><dc:creator> Christopher M Kramer</dc:creator><dc:creator> Robert W Yeh</dc:creator><dc:creator> Beth Martinez</dc:creator><dc:creator> Sarah Mullen</dc:creator><dc:creator> Whitney Huey</dc:creator><dc:creator> Kevin J Anstrom</dc:creator><dc:creator> Hussein R Al-Khalidi</dc:creator><dc:creator> Sreekanth Vemulapalli</dc:creator><dc:creator> PRECISE Investigators</dc:creator><dc:date> 2023-08-23</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease: The PRECISE Randomized Clinical Trial</dc:title><dc:identifier> pmid:37610731</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.2595</dc:identifier></item><item><title> The Need for Global Optimization of Heart Failure Therapy: Some Differences Do Not Matter</title><link/> https://pubmed.ncbi.nlm.nih.gov/37610399/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 2:S0735-1097(23)05963-6. doi: 10.1016/j.jacc.2023.06.007. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37610399/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610399</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.007>10.1016/j.jacc.2023.06.007</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37610399</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Javed Butler</dc:creator><dc:creator> Muhammad Shahzeb Khan</dc:creator><dc:creator> Gregg C Fonarow</dc:creator><dc:date> 2023-08-23</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> The Need for Global Optimization of Heart Failure Therapy: Some Differences Do Not Matter</dc:title><dc:identifier> pmid:37610399</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.007</dc:identifier></item><item><title> Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/37610398/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 2:S0735-1097(23)05964-8. doi: 10.1016/j.jacc.2023.05.056. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Because clinical characteristics and prognosis vary by geographic region in patients with heart failure (HF), the response to treatment may also vary. A previous report suggested that the efficacy of sodium-glucose cotransporter-2 inhibitor efficacy in heart failure with reduced ejection fraction (HFrEF) may be modified by region. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The goal of this study was to examine the efficacy and safety of dapagliflozin in patients with HF according to geographic region. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We conducted a patient-level pooled analysis of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trials, which evaluated the effects of dapagliflozin in HFrEF and heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF), respectively. The primary outcome was the composite of worsening HF or cardiovascular death. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 11,007 patients, 5,159 (46.9%) were enrolled in Europe, 1,528 (13.9%) in North America, 1,998 (18.2%) in South America, and 2,322 (21.1%) in Asia. The rate of the primary outcome (per 100 person-years) was higher in North America (13.9 [95% CI: 12.5-15.4]) than in other regions: Europe 10.8 (95% CI: 10.1-11.5), South America 10.0 (95% CI: 9.0-11.1), and Asia 10.5 (95% CI: 9.5-11.5). The benefit of dapagliflozin on the primary outcome was not modified by region: dapagliflozin vs placebo HR: Europe, 0.85 (95% CI: 0.75-0.96); North America, 0.75 (95% CI: 0.61-0.93); South America, 0.72 (95% CI: 0.58-0.89); and Asia, 0.74 (95% CI: 0.61-0.91) (P interaction = 0.40). This was the same when evaluated separately for HFrEF (P interaction = 0.39) and HFmrEF/HFpEF (P interaction = 0.84). Patients in North America discontinued randomized treatment more frequently than did those elsewhere (placebo discontinuation: 21.8% in North America vs 6.4% in South America), but discontinuation rates did not differ between placebo and dapagliflozin by region. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37610398/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37610398</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.056>10.1016/j.jacc.2023.05.056</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37610398</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Toru Kondo</dc:creator><dc:creator> Xiaowen Wang</dc:creator><dc:creator> Mingming Yang</dc:creator><dc:creator> Pardeep S Jhund</dc:creator><dc:creator> Brian L Claggett</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:creator> Adrian F Hernandez</dc:creator><dc:creator> Carolyn SP Lam</dc:creator><dc:creator> Silvio E Inzucchi</dc:creator><dc:creator> Felipe A Martinez</dc:creator><dc:creator> Rudolf A de Boer</dc:creator><dc:creator> Mikhail N Kosiborod</dc:creator><dc:creator> Akshay S Desai</dc:creator><dc:creator> Lars Køber</dc:creator><dc:creator> Piotr Ponikowski</dc:creator><dc:creator> Marc S Sabatine</dc:creator><dc:creator> Anna Maria Langkilde</dc:creator><dc:creator> Magnus Petersson</dc:creator><dc:creator> Natalia Zaozerska</dc:creator><dc:creator> Erasmus Bachus</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:creator> John JV McMurray</dc:creator><dc:date> 2023-08-23</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure</dc:title><dc:identifier> pmid:37610398</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.056</dc:identifier></item><item><title> Abnormal Lymphatic Sphingosine-1-Phosphate Signaling Aggravates Lymphatic Dysfunction and Tissue Inflammation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37609838/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> CONCLUSION: This study suggests that reduction of the LEC S1P signaling aggravates lymphedema by enhancing LEC adhesion and amplifying pathogenic CD4 T-cell responses. P-selectin inhibitors are suggested as a possible treatment for this pervasive condition. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Aug 23. doi: 10.1161/CIRCULATIONAHA.123.064181. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Lymphedema is a global health problem with no effective drug treatment. Enhanced T-cell immunity and abnormal lymphatic endothelial cell (LEC) signaling are promising therapeutic targets for this condition. Sphingosine-1-phosphate (S1P) mediates a key signaling pathway required for normal LEC function, and altered S1P signaling in LECs could lead to lymphatic disease and pathogenic T-cell activation. Characterizing this biology is relevant for developing much needed therapies. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Human and mouse lymphedema was studied. Lymphedema was induced in mice by surgically ligating the tail lymphatics. Lymphedematous dermal tissue was assessed for S1P signaling. To verify the role of altered S1P signaling effects in lymphatic cells, LEC-specific <i>S1pr1</i> -deficient ( <i>S1pr1</i> <sup>LECKO</sup> ) mice were generated. Disease progression was quantified by tail-volumetric and -histopathologic measurements over time. LECs from mice and humans, with S1P signaling inhibition, were then cocultured with CD4 T cells, followed by an analysis of CD4 T-cell activation and pathway signaling. Last, animals were treated with a monoclonal antibody specific to P-selectin to assess its efficacy in reducing lymphedema and T-cell activation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Human and experimental lymphedema tissues exhibited decreased LEC S1P signaling through S1P receptor 1 (S1PR1). LEC <i>S1pr1</i> loss-of-function exacerbated lymphatic vascular insufficiency, tail swelling, and increased CD4 T-cell infiltration in mouse lymphedema. LECs, isolated from <i>S1pr1</i> <sup>LECKO</sup> mice and cocultured with CD4 T cells, resulted in augmented lymphocyte differentiation. Inhibiting S1PR1 signaling in human dermal LECs promoted T-helper type 1 and 2 (Th1 and Th2) cell differentiation through direct cell contact with lymphocytes. Human dermal LECs with dampened S1P signaling exhibited enhanced P-selectin, an important cell adhesion molecule expressed on activated vascular cells. In vitro, P-selectin blockade reduced the activation and differentiation of Th cells cocultured with <i>shS1PR1</i> -treated human dermal LECs. P-selectin-directed antibody treatment improved tail swelling and reduced Th1/Th2 immune responses in mouse lymphedema. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This study suggests that reduction of the LEC S1P signaling aggravates lymphedema by enhancing LEC adhesion and amplifying pathogenic CD4 T-cell responses. P-selectin inhibitors are suggested as a possible treatment for this pervasive condition.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37609838/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37609838</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064181>10.1161/CIRCULATIONAHA.123.064181</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37609838</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Dongeon Kim</dc:creator><dc:creator> Wen Tian</dc:creator><dc:creator> Timothy Ting-Hsuan Wu</dc:creator><dc:creator> Menglan Xiang</dc:creator><dc:creator> Ryan Vinh</dc:creator><dc:creator> Jason Lon Chang</dc:creator><dc:creator> Shenbiao Gu</dc:creator><dc:creator> Seunghee Lee</dc:creator><dc:creator> Yu Zhu</dc:creator><dc:creator> Torrey Guan</dc:creator><dc:creator> Emilie Claire Schneider</dc:creator><dc:creator> Evan Bao</dc:creator><dc:creator> J Brandon Dixon</dc:creator><dc:creator> Peter Kao</dc:creator><dc:creator> Junliang Pan</dc:creator><dc:creator> Stanley G Rockson</dc:creator><dc:creator> Xinguo Jiang</dc:creator><dc:creator> Mark Robert Nicolls</dc:creator><dc:date> 2023-08-23</dc:date><dc:source> Circulation</dc:source><dc:title> Abnormal Lymphatic Sphingosine-1-Phosphate Signaling Aggravates Lymphatic Dysfunction and Tissue Inflammation</dc:title><dc:identifier> pmid:37609838</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064181</dc:identifier></item><item><title> Long-term risk for atrial and ventricular arrhythmias: a cardinal manifestation of &#39;the epileptic heart&#39;</title><link/> https://pubmed.ncbi.nlm.nih.gov/37608403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 22:ehad524. doi: 10.1093/eurheartj/ehad524. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37608403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37608403</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad524>10.1093/eurheartj/ehad524</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37608403</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Richard L Verrier</dc:creator><dc:creator> Trudy D Pang</dc:creator><dc:creator> Steven C Schachter</dc:creator><dc:date> 2023-08-23</dc:date><dc:source> European heart journal</dc:source><dc:title> Long-term risk for atrial and ventricular arrhythmias: a cardinal manifestation of &#39;the epileptic heart&#39;</dc:title><dc:identifier> pmid:37608403</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad524</dc:identifier></item><item><title> Brain-wide representations of behavior spanning multiple timescales and states in C. elegans</title><link/> https://pubmed.ncbi.nlm.nih.gov/37607537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> Changes in an animal&#39;s behavior and internal state are accompanied by widespread changes in activity across its brain. However, how neurons across the brain encode behavior and how this is impacted by state is poorly understood. We recorded brain-wide activity and the diverse motor programs of freely moving C. elegans and built probabilistic models that explain how each neuron encodes quantitative behavioral features. By determining the identities of the recorded neurons, we created an atlas of... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 14:S0092-8674(23)00850-4. doi: 10.1016/j.cell.2023.07.035. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Changes in an animal&#39;s behavior and internal state are accompanied by widespread changes in activity across its brain. However, how neurons across the brain encode behavior and how this is impacted by state is poorly understood. We recorded brain-wide activity and the diverse motor programs of freely moving C. elegans and built probabilistic models that explain how each neuron encodes quantitative behavioral features. By determining the identities of the recorded neurons, we created an atlas of how the defined neuron classes in the C. elegans connectome encode behavior. Many neuron classes have conjunctive representations of multiple behaviors. Moreover, although many neurons encode current motor actions, others integrate recent actions. Changes in behavioral state are accompanied by widespread changes in how neurons encode behavior, and we identify these flexible nodes in the connectome. Our results provide a global map of how the cell types across an animal&#39;s brain encode its behavior.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37607537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37607537</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.035>10.1016/j.cell.2023.07.035</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37607537</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Adam A Atanas</dc:creator><dc:creator> Jungsoo Kim</dc:creator><dc:creator> Ziyu Wang</dc:creator><dc:creator> Eric Bueno</dc:creator><dc:creator> McCoy Becker</dc:creator><dc:creator> Di Kang</dc:creator><dc:creator> Jungyeon Park</dc:creator><dc:creator> Talya S Kramer</dc:creator><dc:creator> Flossie K Wan</dc:creator><dc:creator> Saba Baskoylu</dc:creator><dc:creator> Ugur Dag</dc:creator><dc:creator> Elpiniki Kalogeropoulou</dc:creator><dc:creator> Matthew A Gomes</dc:creator><dc:creator> Cassi Estrem</dc:creator><dc:creator> Netta Cohen</dc:creator><dc:creator> Vikash K Mansinghka</dc:creator><dc:creator> Steven W Flavell</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> Cell</dc:source><dc:title> Brain-wide representations of behavior spanning multiple timescales and states in C. elegans</dc:title><dc:identifier> pmid:37607537</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.035</dc:identifier></item><item><title> A pan-cancer single-cell panorama of human natural killer cells</title><link/> https://pubmed.ncbi.nlm.nih.gov/37607536/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> Natural killer (NK) cells play indispensable roles in innate immune responses against tumor progression. To depict their phenotypic and functional diversities in the tumor microenvironment, we perform integrative single-cell RNA sequencing analyses on NK cells from 716 patients with cancer, covering 24 cancer types. We observed heterogeneity in NK cell composition in a tumor-type-specific manner. Notably, we have identified a group of tumor-associated NK cells that are enriched in tumors, show... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Aug 15:S0092-8674(23)00849-8. doi: 10.1016/j.cell.2023.07.034. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Natural killer (NK) cells play indispensable roles in innate immune responses against tumor progression. To depict their phenotypic and functional diversities in the tumor microenvironment, we perform integrative single-cell RNA sequencing analyses on NK cells from 716 patients with cancer, covering 24 cancer types. We observed heterogeneity in NK cell composition in a tumor-type-specific manner. Notably, we have identified a group of tumor-associated NK cells that are enriched in tumors, show impaired anti-tumor functions, and are associated with unfavorable prognosis and resistance to immunotherapy. Specific myeloid cell subpopulations, in particular LAMP3 <sup>+</sup> dendritic cells, appear to mediate the regulation of NK cell anti-tumor immunity. Our study provides insights into NK-cell-based cancer immunity and highlights potential clinical utilities of NK cell subsets as therapeutic targets.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37607536/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37607536</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.07.034>10.1016/j.cell.2023.07.034</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37607536</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Fei Tang</dc:creator><dc:creator> Jinhu Li</dc:creator><dc:creator> Lu Qi</dc:creator><dc:creator> Dongfang Liu</dc:creator><dc:creator> Yufei Bo</dc:creator><dc:creator> Shishang Qin</dc:creator><dc:creator> Yuhui Miao</dc:creator><dc:creator> Kezhuo Yu</dc:creator><dc:creator> Wenhong Hou</dc:creator><dc:creator> Jianan Li</dc:creator><dc:creator> Jirun Peng</dc:creator><dc:creator> Zhigang Tian</dc:creator><dc:creator> Linnan Zhu</dc:creator><dc:creator> Hui Peng</dc:creator><dc:creator> Dongfang Wang</dc:creator><dc:creator> Zemin Zhang</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> Cell</dc:source><dc:title> A pan-cancer single-cell panorama of human natural killer cells</dc:title><dc:identifier> pmid:37607536</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.034</dc:identifier></item><item><title> Antithrombotic treatment: personalized antiplatelet therapies and lessons from the gut microbiota</title><link/> https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 22;44(32):3023-3026. doi: 10.1093/eurheartj/ehad521.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37607038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37607038</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad521>10.1093/eurheartj/ehad521</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37607038</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Filippo Crea</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> European heart journal</dc:source><dc:title> Antithrombotic treatment: personalized antiplatelet therapies and lessons from the gut microbiota</dc:title><dc:identifier> pmid:37607038</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad521</dc:identifier></item><item><title> Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management</title><link/> https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> Patient-reported outcomes (PROs) provide important insights into patients&#39; own perspectives about their health and medical condition, and there is evidence that their use can lead to improvements in the quality of care and to better-informed clinical decisions. Their application in cardiovascular populations has grown over the past decades. This statement describes what PROs are, and it provides an inventory of disease-specific and domain-specific PROs that have been developed for cardiovascular... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 22:ehad514. doi: 10.1093/eurheartj/ehad514. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Patient-reported outcomes (PROs) provide important insights into patients&#39; own perspectives about their health and medical condition, and there is evidence that their use can lead to improvements in the quality of care and to better-informed clinical decisions. Their application in cardiovascular populations has grown over the past decades. This statement describes what PROs are, and it provides an inventory of disease-specific and domain-specific PROs that have been developed for cardiovascular populations. International standards and quality indices have been published, which can guide the selection of PROs for clinical practice and in clinical trials and research; patients as well as experts in psychometrics should be involved in choosing which are most appropriate. Collaborations are needed to define criteria for using PROs to guide regulatory decisions, and the utility of PROs for comparing and monitoring the quality of care and for allocating resources should be evaluated. New sources for recording PROs include wearable digital health devices, medical registries, and electronic health record. Advice is given for the optimal use of PROs in shared clinical decision-making in cardiovascular medicine, and concerning future directions for their wider application.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37606064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37606064</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad514>10.1093/eurheartj/ehad514</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37606064</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Philip Moons</dc:creator><dc:creator> Tone M Norekvål</dc:creator><dc:creator> Elena Arbelo</dc:creator><dc:creator> Britt Borregaard</dc:creator><dc:creator> Barbara Casadei</dc:creator><dc:creator> Bernard Cosyns</dc:creator><dc:creator> Martin R Cowie</dc:creator><dc:creator> Donna Fitzsimons</dc:creator><dc:creator> Alan G Fraser</dc:creator><dc:creator> Tiny Jaarsma</dc:creator><dc:creator> Paulus Kirchhof</dc:creator><dc:creator> Josepa Mauri</dc:creator><dc:creator> Richard Mindham</dc:creator><dc:creator> Julie Sanders</dc:creator><dc:creator> Francois Schiele</dc:creator><dc:creator> Aleksandra Torbica</dc:creator><dc:creator> Ann Dorthe Zwisler</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> European heart journal</dc:source><dc:title> Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management</dc:title><dc:identifier> pmid:37606064</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad514</dc:identifier></item><item><title> Brain α2δ-1-Bound NMDA Receptors Drive Calcineurin Inhibitor-Induced Hypertension</title><link/> https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230823203531&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: These findings indicate that α2δ-1 is essential for calcineurin inhibitor-induced increases in synaptic NMDAR activity in PVN presympathetic neurons and sympathetic outflow. Thus, α2δ-1 and α2δ-1-bound NMDARs represent new targets for treating calcineurin inhibitor-induced hypertension. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Aug 22. doi: 10.1161/CIRCRESAHA.123.322562. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Calcineurin is highly enriched in immune T cells and in the nervous system. Calcineurin inhibitors, including cyclosporine and tacrolimus (FK506), are the cornerstone of immunosuppressive regimens for preserving transplanted organs and tissues. However, these drugs often cause persistent hypertension owing to excess sympathetic outflow, which is maintained by N-methyl-D-aspartate receptor (NMDAR)-mediated excitatory input to the hypothalamic paraventricular nucleus (PVN). It is unclear how calcineurin inhibitors increase NMDAR activity in the PVN to augment sympathetic vasomotor activity. α2δ-1 (encoded by the <i>Cacna2d1</i> gene), known colloquially as a calcium channel subunit, is a newly discovered NMDAR-interacting protein. Here, we determined whether α2δ-1 plays a role in calcineurin inhibitor-induced synaptic NMDAR hyperactivity in the PVN and hypertension development. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS AND RESULTS: Immunoblotting and coimmunoprecipitation assays revealed that prolonged treatment with FK506 in rats significantly increased protein levels of α2δ-1, GluN1 (the obligatory NMDAR subunit), and the α2δ-1-GluN1 complex in PVN synaptosomes. These effects were blocked by inhibiting α2δ-1 with gabapentin or interrupting the α2δ-1-NMDAR interaction with an α2δ-1 C-terminus peptide. Whole-cell recordings in brain slices showed that treatment with FK506 potentiated the activity of presynaptic and postsynaptic NMDARs in spinally projecting PVN neurons; such effects were abolished by gabapentin, <i>Cacna2d1</i> knockout, or α2δ-1 C-terminus peptide. Furthermore, microinjection of α2δ-1 C-terminus peptide into the PVN diminished renal sympathetic nerve discharges and arterial blood pressure that had been increased by FK506 treatment. Remarkably, telemetry recording showed that concurrent administration of gabapentin prevented the development of FK506-induced hypertension in rats. Additionally, FK506 treatment induced sustained hypertension in wild-type mice but not in <i>Cacna2d1</i> knockout mice. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: These findings indicate that α2δ-1 is essential for calcineurin inhibitor-induced increases in synaptic NMDAR activity in PVN presympathetic neurons and sympathetic outflow. Thus, α2δ-1 and α2δ-1-bound NMDARs represent new targets for treating calcineurin inhibitor-induced hypertension.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37605933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230823203531&v=2.17.9.post6+86293ac">37605933</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.322562>10.1161/CIRCRESAHA.123.322562</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37605933</guid><pubDate> Tue, 22 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jing-Jing Zhou</dc:creator><dc:creator> Jian-Ying Shao</dc:creator><dc:creator> Shao-Rui Chen</dc:creator><dc:creator> Hui-Lin Pan</dc:creator><dc:date> 2023-08-22</dc:date><dc:source> Circulation research</dc:source><dc:title> Brain α2δ-1-Bound NMDA Receptors Drive Calcineurin Inhibitor-Induced Hypertension</dc:title><dc:identifier> pmid:37605933</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322562</dc:identifier></item></channel></rss>